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Abstract
Background: Two replicate, double-blind, placebo-controlled, 6-week crossover studies assessed the effect of the
once-daily long-acting β2-agonist olodaterol 5 μg and 10 μg on constant work-rate cycle endurance in patients
with moderate to very severe chronic obstructive pulmonary disease.
Methods: Patients received placebo, olodaterol 5 μg once daily (QD) and olodaterol 10 μg QD in a randomised
order for 6 weeks each, with a 2-week washout period in between. The primary end point was change in
endurance time during constant work-rate cycle ergometry to symptom limitation at 75 % maximal work capacity
after 6 weeks of treatment (2 h post-dose), based on log10-transformed data. Key secondary end points were
inspiratory capacity at isotime and intensity of breathing discomfort at isotime.
Results: 151 and 157 patients were randomised and treated in Studies 1222.37 and 1222.38, respectively, with 147
and 154 being included in the full analysis sets. Mean endurance time at week 6 was increased compared to
placebo by 14.0 % (Study 1222.37; p < 0.001) and 11.8 % (Study 1222.38; p < 0.01) with olodaterol 5 μg, and by
13.8 % (Study 1222.37; p < 0.001) and 10.5 % (Study 1222.38; p < 0.01) with olodaterol 10 μg. Inspiratory capacity at
isotime increased with olodaterol 5 μg (Study 1222.37, 0.182 L, p < 0.0001; Study 1222.38, 0.084 L, p < 0.05) and
10 μg (Study 1222.37, 0.174 L; Study 1222.38, 0.166 L; both studies, p < 0.0001), and breathing discomfort was
significantly reduced in Study 1222.37 (olodaterol 5 μg, 0.77 Borg units, p < 0.001; olodaterol 10 μg, 0.63 Borg units,
p < 0.01) but not Study 1222.38.
Conclusions: These studies provide further characterisation of the efficacy of olodaterol, showing that
improvements in airflow (forced expiratory volume in 1 s) are associated with increases in inspiratory capacity and
improvements in exercise endurance time.
Trial registrations: NCT01040130 (1222.37) and NCT01040793 (1222.38).
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Background
Expiratory flow limitation is a hallmark of chronic ob-
structive pulmonary disease (COPD) [1]. During periods
of increased ventilatory demand, expiratory flow limita-
tion results in dynamic hyperinflation and is associated
with significant breathing discomfort [2]. Dynamic lung
hyperinflation is seen in the majority of patients with
COPD during cycling [2–4] and may also be present in
daily activities such as walking [5]. Hyperinflation limits
exercise tolerance, which, in turn, reduces patients’ qual-
ity of life [6] and, potentially, survival [7]. As such, im-
proving exercise tolerance is a key therapeutic goal in
COPD [8].
Long-acting β2-agonists (LABAs) and long-acting mus-
carinic antagonists (LAMAs) are well established as main-
tenance therapies for moderate to very severe COPD [8,
9]. Improvements in airflow limitation with both LAMAs
and LABAs are associated with increases in inspiratory
capacity (IC) at rest and during exercise in patients with
COPD (a marker of reduced lung hyperinflation), with re-
sultant reductions in breathing discomfort and improve-
ments in exercise endurance time [2, 10–17].
Olodaterol is a novel LABA with a high affinity for,
and almost full intrinsic activity at, β2 receptors, and a
low affinity and partial agonist activity at β1 receptors
[18, 19]. Its duration of action is ≥24 h, allowing for
once-daily (QD) dosing [20]. Pivotal Phase III trials have
established the long-term efficacy of olodaterol 5 μg and
10 μg QD with respect to lung function (forced expira-
tory volume in 1 s [FEV1]) [21–24].
Studies 1222.37 and 1222.38 were designed to test the
hypothesis that olodaterol reduces airflow limitation
during tidal breathing, reducing hyperinflation and
breathing discomfort experienced during exercise, with
consequent improvement in symptom-limited cycling
exercise endurance.
The aim of these two replicate, 6-week, placebo-
controlled, crossover studies was thus to assess the effects
of olodaterol 5 μg and 10 μg QD, via the RespimatW in-
haler, on constant work-rate cycling exercise endurance in
patients with moderate to very severe COPD.
Methods
Patients
Patients with moderate to very severe COPD (Global ini-
tiative for chronic Obstructive Lung Disease [GOLD] 2–
4) were included in the studies if they met the following
inclusion criteria: persistent airway obstruction with
post-bronchodilator FEV1 <80 % of predicted normal
and post-bronchodilator FEV1/forced vital capacity
[FVC] <70 %; aged 40–75 years; and with a smoking his-
tory of >10 pack-years. At variance with many COPD
exercise endurance trials [2, 12–15, 17], the presence of
static lung hyperinflation (i.e., increased functional
residual capacity [FRC]) was not an entry requirement,
since the intention of the study was to evaluate the ef-
fects of olodaterol on exercise endurance in a broad pa-
tient population. Key exclusion criteria included: a
significant disease other than COPD that could influence
patients’ safety during the study; history of asthma; myo-
cardial infarction in the previous year; unstable or life-
threatening cardiac arrhythmia; or hospitalisation due to
heart failure in the previous year. In addition, patients
were not eligible to take part if their exercise perform-
ance was limited for a reason other than fatigue or dys-
pnoea, such as arthritis, angina pectoris, claudication or
morbid obesity, or if they had any contraindications to
exercise as outlined by the European Respiratory Society
Task Force on clinical exercise testing [25]. Patients with
a cycling endurance time of ≥25 min at pre-
randomisation evaluation were also excluded.
Study design
Studies 1222.37 (NCT01040130) and 1222.38
(NCT01040793) were replicate, multicentre, multi-
national, randomised, double-blind, placebo-controlled,
three-way crossover trials (see Fig. 1 for a schematic of
the study design). Following an initial screening visit,
there was a 2-week baseline period. During the baseline
period and for the rest of the trial, patients were permit-
ted to continue with short-acting muscarinic antagonists
(at least 8-h washout required prior to clinic visits), in-
haled corticosteroids and xanthines, and rescue short-
acting β2-agonists (open-label salbutamol), but not
LAMAs or LABAs.
Patients received each of the following treatments for
6 weeks in a randomised order: olodaterol 5 μg QD, olo-
daterol 10 μg QD and placebo QD. Olodaterol was ad-
ministered as two actuations of the RespimatW inhaler.
Between treatment periods, there was a 2-week washout
period where patients continued with their permitted
therapy. Clinic visits were scheduled on days 1 and 43 of
each treatment period, with a follow-up visit 2 weeks
after the last treatment period. In the case of early dis-
continuation, a follow-up visit was completed 2 weeks
after the final dose of study medication.
The studies were carried out in accordance with the
principles of the Declaration of Helsinki and the Inter-
national Conference on Harmonisation Harmonised Tri-
partite Guideline for Good Clinical Practice, and written,
informed consent was obtained from each patient.
Exercise testing
At the initial screening visit, maximum work capacity
(Wcap) was determined for each patient during incre-
mental cycle ergometry conducted as described by
O’Donnell and Webb [26]. Prior to randomisation, pa-
tients performed a ‘training’ constant work-rate cycle
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endurance test to symptom limitation at 75 % of Wcap
and, ≥2 days later, performed a second constant work-
rate cycle endurance test to determine pre-treatment
baseline endurance time. Constant work-rate cycle en-
durance tests at 75 % Wcap were repeated on day 43 of
each treatment period at 2 h (+ ≤15 min) after inhalation
of the study medication. To limit the number of exercise
tests performed by patients, the pre-randomisation test
was used as baseline for all treatment comparisons. In-
tensity of breathing discomfort using the Borg category-
ratio scale was recorded and IC was measured at rest, at
2-min intervals during exercise and at the end of exer-
cise, as previously described [13]. Heart rate, blood pres-
sure and electrocardiogram measurements were also
recorded during exercise. After completing each exercise
test, patients indicated the reason for stopping exercise
using a simple questionnaire (due to leg and/or breath-
ing discomfort, chest pain or other reason).
Pulmonary function testing
Spirometry (FEV1, FVC and peak expiratory flow) was
performed at screening and on days 1 and 43 of each
treatment period, 30 min pre-dose (trough measure-
ment) and 1 h post-dose.
Body plethysmography was performed on days 1 and
43 of each treatment period 30 min pre-dose (trough
measurement) and 1 h post-dose (prior to spirometry),
according to the methods and calibration described by
Coates et al. [27] to determine FRC and IC, with total
lung capacity calculated as mean FRC + largest IC of
three plethysmographic measurements.
Outcome measures
The primary end point was log10-transformed endurance
time during constant work-rate cycle ergometry to
symptom limitation at 75 % Wcap after 6 weeks of treat-
ment. Key secondary end points were IC and intensity of
breathing discomfort at isotime. Isotime was defined for
each patient as the furthest exercise time that they
reached in all of the constant work-rate tests (baseline
and all treatment periods), i.e., their shortest ever endur-
ance time.
In addition, two post hoc subgroup analyses were per-
formed using combined data from Studies 1222.37 and
1222.38 to investigate exercise time in patients with
static hyperinflation (FRC ≥120 % predicted) and with
static and/or dynamic hyperinflation (defined as IC at
rest – IC end exercise >100 mL [28]). Additional post
hoc analyses (using data from the individual studies)
were conducted to compare exercise time in GOLD 2
patients to GOLD 3 or 4 patients.
Statistical analyses
For the primary end point, adjusted means of endurance
time on a log10 scale were tested using a mixed model for
repeated measures, based on previous studies showing
WashoutRun-in
Screening      Randomisation
Washout
Crossover study - 3 treatments given in random order:
olodaterol 5 µg QD; olodaterol 10 µg QD; placebo QD
Treatment 1 Treatment 2 Treatment 3
Follow-up
6 weeks
2 weeks
Incremental cycle ergometry to determine Wcap
Constant work-rate endurance test
Baseline
Fig. 1 Trial design for Studies 1222.37 and 1222.38. QD once daily, Wcap maximum work capacity
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that endurance time has a log normal distribution [4]. The
model included treatment and period as fixed effects and
patient as a random effect. Log10-transformed study base-
line endurance time was added as a covariate.
Based on a predicted standard deviation of within-
subject treatment difference for endurance time on a
log10 scale of ~0.181 s, with a Type I error rate of 0.05
(two-sided), 102 patients were required to detect a dif-
ference in endurance time of 15 %. Allowing for possibly
higher standard deviation and patient dropout, 150 pa-
tients needed to be randomised in each study.
The primary analysis was conducted on the full ana-
lysis set, which included all patients with baseline and
any evaluable post-dose endurance time data. A sensitiv-
ity analysis for the primary end point was performed
based on a per-protocol set, which included patients
with no significant protocol violations. No imputation
was made for missing endurance time values.
Secondary analyses used the mixed model for repeated
measures described above for all continuous variables
but without using a log10 scale and with non-
transformed study baseline as a covariate. To calculate
the IC and Borg scale values at isotime when no value
was available at that exact time point, interpolation was
to be used if a value was available afterwards. Missing IC
or Borg scale values were imputed using last observation
carried forward.
The primary and key secondary end points were
included in a hierarchical testing strategy, shown in
Additional file 1: Figure S1, with each test considered
confirmatory only if all of the previous tests were
successful. There was no alpha protection for multiple
testing for the additional secondary end points.
Results
Patient disposition and baseline characteristics
A total of 151 patients (from 19 sites in five countries)
and 157 patients (from 19 sites in five countries) were ran-
domised into the treatment phases in Study 1222.37 and
Study 1222.38, respectively (Additional file 1: Figures S2a
and b). Overall, 147 (Study 1222.37) and 154 (Study
1222.38) patients were included in the full analysis set for
primary analyses. At least 95 % (Study 1222.37) and 94 %
(Study 1222.38) of patients in each treatment arm com-
pleted the full 6 weeks; patients who discontinued a treat-
ment period were permitted to continue to the next
treatment (Additional file 1: Figures S2a and b).
Baseline patient characteristics are shown in Table 1.
Patients in Study 1222.38 had a higher baseline mean
pre-bronchodilator FEV1 and lower mean change from
pre- to post-bronchodilator FEV1 than in Study 1222.37
(Table 1). While there was no specific requirement for
the presence of static lung hyperinflation at study entry,
108 (71.5 %) patients in Study 1222.37 and 116 (73.9 %)
patients in Study 1222.38 did exhibit resting lung hyper-
inflation (FRC ≥120 % predicted normal at baseline)
(Table 1). Relevant parameters during the baseline con-
stant work-rate cycle test are shown in Table 2. An over-
view of pulmonary medication use prior to study
enrolment is presented in Additional file 1: Table S1.
Efficacy
Endurance time
The assumption of a log normal distribution was con-
firmed in both studies, with clear differences between
the arithmetic mean and median endurance times at
baseline and after 6 weeks of treatment in all treatment
arms (Additional file 1: Table S2, Figure S3); thus the
validity of the pre-specified primary analysis based on
log10-transformed endurance time was confirmed.
Log10-transformed mean endurance time at 6 weeks
significantly increased by 11.8–14.0 % with olodaterol
5 μg and by 10.5–13.8 % with olodaterol 10 μg when
Table 1 Baseline demographics and patient characteristics
(treated seta)
Study
1222.37
Study
1222.38
(n = 151) (n = 157)
Male, n (%) 116 (76.8) 116 (73.9)
Mean (SD) age, years 60.6 (7.7) 60.6 (7.7)
Smoking status, n (%)
Ex-smoker
Current smoker
84 (55.6)
67 (44.4)
92 (58.6)
65 (41.4)
Mean (SD) smoking history, pack-years 45.3 (22.5) 50.0 (29.0)
Mean (SD) pre-bronchodilator at screening
FEV1, L
FEV1 % predicted
1.46 (0.54)
48.5 (14.5)
1.56 (0.53)
51.6 (14.2)
Mean (SD) post-bronchodilator at screening
FEV1, L
Change from pre- to post-bronchodilator
1.66 (0.55) 1.70 (0.53)
FEV1, L 0.19 (0.18) 0.14 (0.19)
FEV1 % predicted 55.1 (14.4) 56.1 (13.1)
Change from pre- to post-bronchodilator
FEV1, % 15.7 (14.7) 10.9 (14.3)
GOLD, n (%)
1 (≥80 %)
2 (50– <80 %)
3 (30– <50 %)
4 (<30 %)
0 (0.0)
100 (66.2)
43 (28.5)
8 (5.3)
1 (0.6)b
111 (70.7)
41 (26.1)
4 (2.5)
Patients with FRC ≥120 % predicted normal,
n (%)
108 (71.5) 116 (73.9)
a4 patients in Study 1222.37 and 3 in Study 1222.38 were included in the
treated set but not the full analysis set because they did not have baseline or
primary end point data; b1 patient with a predicted FEV1 of 80.4 %. This was
classed as a protocol violation; the patient was included in the full analysis set
but was excluded from the per protocol set
SD standard deviation, FEV1 forced expiratory volume in 1 s, GOLD Global
initiative for chronic Obstructive Lung Disease, FRC functional residual capacity
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compared to placebo (Fig. 2). Arithmetic and geometric
mean endurance times are shown in Additional file 1:
Table S2.
There were no significant differences in endurance
time between olodaterol 5 μg and 10 μg for the primary
end point in either study. The results of the per-protocol
set analysis were consistent with the primary analysis.
Changes in endurance time in patients who were
GOLD 2 and patients who were GOLD 3 or 4 are shown
in Additional file 1: Table S3. There were generally
slightly higher increases in endurance time with oloda-
terol in GOLD 3/4 patients than in GOLD 2 patients.
In patients from Studies 1222.37 and 1222.38 with
static hyperinflation at baseline (FRC ≥120 % pre-
dicted normal; n = 224), log10-transformed mean en-
durance time at 6 weeks significantly increased by
13.2 % (p < 0.0001) and 12.2 % (p = 0.0002) with olo-
daterol 5 μg and 10 μg, respectively, from a geomet-
ric mean baseline endurance time of 376.4 s. In a
subgroup of patients from both studies with static
and/or dynamic hyperinflation (defined as IC at rest
– IC end exercise >100 mL [28]; n = 274), log10
mean endurance time increased from geometric
mean baseline of 388.2 s by 13.3 % (p < 0.0001) and
12.1 % (p < 0.0001) with olodaterol 5 μg and 10 μg,
respectively. These improvements were of similar
magnitude to those observed in the whole popula-
tion of patients.
IC and breathing discomfort
In both studies, IC increased with olodaterol 5 μg and
10 μg at rest (prior to exercise), at isotime and at end-
exercise (Fig. 3). There was a statistically significant
increase in IC at isotime compared to placebo with
olodaterol 5 μg (0.182 L; p < 0.0001) and 10 μg (0.174 L;
p < 0.0001) in Study 1222.37, and with olodaterol 5 μg
(0.084 L; p < 0.05) and 10 μg (0.166 L; p < 0.0001) in
Study 1222.38 (Fig. 3).
There was a significant reduction in the intensity of
breathing discomfort at isotime compared to placebo
in Study 1222.37 of 0.77 Borg units with olodaterol
5 μg (p < 0.001) and 0.63 Borg units with olodaterol
10 μg (p < 0.01); there were no significant differences
in Study 1222.38 (Table 3).
Spirometry and body plethysmography
In both studies, FEV1 and FVC significantly improved at
trough (30 min pre-dose) and at 1 h post-dose with olo-
daterol 5 μg and 10 μg compared to placebo (Table 4).
Peak expiratory flow data are shown in Additional file 1:
Table S4.
Both studies showed statistically significant increases
in IC measured using body plethysmography for oloda-
terol 5 μg and 10 μg compared to placebo at 30 min
pre-dose and 1 h post-dose, with corresponding de-
creases in FRC (Table 5). The results of IC at 1 h post-
dose using body plethysmography (Table 5) were similar
to the results of IC 2 h post-dose measured using spir-
ometry immediately prior to exercise (Fig. 3).
Safety and tolerability
Adverse events
Across both studies, incidences of adverse events, ser-
ious adverse events and adverse events leading to dis-
continuation with olodaterol 5 μg and 10 μg were
similar to placebo (Table 6). The most common ad-
verse event was COPD exacerbation, occurring in
6.7–7.0 %, 6.0–7.5 % and 2.7–4.9 % of patients with
placebo, olodaterol 5 μg and olodaterol 10 μg, re-
spectively, in both studies. Three patients in each
treatment group in Study 1222.37 and three patients
in the placebo group, eight with olodaterol 5 μg and
three with olodaterol 10 μg in Study 1222.38 had ser-
ious adverse events. None of the serious adverse
events in Study 1222.37 and one in Study 1222.38
(atrial fibrillation in a patient taking olodaterol 5 μg)
were considered by the investigator to be related to
the study drug.
There were no clinically relevant changes in laboratory
parameters, vital signs or electrocardiogram in either
study. There were no deaths in Study 1222.37 and one
death of unknown cause after 5 days of treatment in the
olodaterol 10 μg group in Study 1222.38.
Table 2 Baseline exercise parameters (full analysis set)
Study
1222.37
Study
1222.38
(n = 147) (n = 154)
Geometric mean (SE) endurance time, s 414.2 (18.5) 373.9 (13.5)
Arithmetic mean (SE) endurance time, s 478.2 (21.9) 415.5 (17.4)
Mean (SE) IC, L
Pre-exercise
Isotime
End-exercise
2.29 (0.06)
2.04 (0.07)
2.00 (0.06)
2.37 (0.06)
2.14 (0.06)
2.13 (0.06)
Mean (SE) breathing discomfort, Borg
units
Pre-exercise
Isotime
End-exercise
0.32 (0.05)
5.27 (0.21)
7.20 (0.20)
0.31 (0.05)
5.53 (0.19)
7.51 (0.18)
Mean (SE) leg discomfort, Borg units
Pre-exercise
Isotime
End-exercise
0.26 (0.07)
5.27 (0.22)
7.05 (0.23)
0.18 (0.04)
4.42 (0.22)
6.01 (0.24)
Locus of symptom limitation, n (%)
Breathing discomfort
Leg discomfort
Breathing and leg discomfort
None
52 (35.4)
40 (27.2)
52 (35.4)
3 (2.0)
81 (52.6)
26 (16.9)
42 (27.3)
5 (3.2)
SE standard error, IC inspiratory capacity
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Discussion
Results from these two replicate trials confirm that treat-
ment with olodaterol improves exercise endurance time
during constant work-rate cycle ergometry in patients
with COPD. The improvements in endurance time were
observed in patients with a broad range of disease char-
acteristics, including GOLD 2 patients with moderate
disease (69 % of the total patient population) and pa-
tients with and without static lung hyperinflation (89 %
of the total patient population), supporting the applica-
tion of our results to a larger COPD population. There
were no differences in endurance time between patients
receiving olodaterol 5 μg and 10 μg, and both doses
were well tolerated. The improved endurance time with
olodaterol was associated with an increase in IC that
was present at rest (prior to exercise) and was main-
tained during exercise, which has also been observed
with other bronchodilators [13].
Since early exercise studies of tiotropium in patients
with COPD [13, 15], constant work-rate exercise proto-
cols to symptom limitation, with serial measurements of
IC and breathing discomfort, have frequently been used
to investigate the effects of long-acting bronchodilators
on lung hyperinflation, exertional dyspnoea and
symptom-limited exercise capacity [12, 14, 15, 17,
29–31] (NCT01533922 and NCT01533935; manuscript
in preparation). The consistent demonstration of a
significant relationship between IC and endurance time
[13] has led to an increased understanding of the mech-
anistic relationship between the primary effects of
bronchodilators in improving expiratory flow, and the
consequent reductions in lung hyperinflation and exer-
tional breathing discomfort, which in turn lead to in-
creases in the time to reach intolerable symptom
intensity during exercise.
An important methodological consideration in relation
to the current trials is that statistical analyses were per-
formed on log10-transformed endurance time data, un-
like previous trials that have assessed cycling endurance
time in COPD. Although these analyses are justified by
the fact that endurance time during constant work-rate
exercise is asymmetrically distributed around the mean,
with a significant skew towards long exercise endurance
times (as has been previously reported [4] and confirmed
in the present trials), this approach complicates compar-
isons with previous trials. For the purpose of facilitating
comparisons across studies, we also report the arith-
metic mean treatment effects of olodaterol (Additional
file 1: Table S2). The arithmetic differences in endurance
time for olodaterol, compared to placebo, range from 40
to 64 s. Although these may appear to be at the lower
end of what is typically reported with other long-acting
bronchodilators, including tiotropium, glycopyrronium
bromide, aclidinium bromide, salmeterol and indacaterol
[12, 14, 15, 17, 29, 30], they are within the estimated
range for a clinically meaningful difference, compared to
Fig. 2 Adjusted geometric mean symptom-limited endurance time after 6 weeks in Studies 1222.37 and 1222.38 (full analysis set).
SE standard error
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(a)
(b)
Fig. 3 Adjusted mean inspiratory capacity after 6 weeks in (a) Study 1222.37 and (b) Study 1222.38 (full analysis set). SE standard error
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placebo, of 46–105 s for endurance time, as proposed by
the European Respiratory Society task force on out-
comes in COPD [32].
Caution should be exercised when comparing in-
creases in endurance time across studies due to a
number of confounding factors, including differences
in patient characteristics and phenotypes. Variation
in the improvement in expiratory flow following
bronchodilation from one study population to an-
other may contribute to the observed differences in
effect size between studies. In light of this, an
important methodological difference between our
studies and previous exercise trials was that the
presence of static lung hyperinflation was not a
prerequisite for participation in our trials. Also at
variance with previous trials [13, 15], patients with
post-bronchodilator FEV1 ≤80 % predicted were per-
mitted in our trials, including a larger proportion of
GOLD 2 patients (69 % of the total patient popula-
tion). Although olodaterol also enhanced exercise
capacity in these patients, the inclusion of patients
with milder COPD may have mitigated the observed
Table 3 Adjusted mean breathing discomfort measured using the Borg category-ratio scale at isotime after 6 weeks
(full analysis set)
Isotime
Treatment n Mean time, mm:ssa Borg (SE) p value versus placebo
Study 1222.37
Baseline 5.27 (0.21)
Placebo 136 05:58 5.87 (0.19)
Olodaterol 5 μg 140 06:02 5.10 (0.18) 0.0007
Olodaterol 10 μg 136 06:05 5.24 (0.19) 0.0051
Study 1222.38
Baseline 5.53 (0.19)
Placebo 146 05:29 5.59 (0.18)
Olodaterol 5 μg 141 05:25 5.25 (0.18) 0.1176
Olodaterol 10 μg 140 05:22 5.52 (0.18) 0.7591
aDue to differences in the number of patients between treatment groups, slight differences in mean time are observed
SE standard error
Table 4 Adjusted mean FEV1 and FVC outcomes at 6 weeks (full analysis set)
FEV1 FVC
Treatment Planned time (min) Mean (SE), L Mean (SE) difference
from placebo
p value Mean (SE), L Mean (SE) difference
from placebo
p value
Study 1222.37
Placebo −0.30 (pre-dose/trough) 1.475 (0.017)a 3.212 (0.037)b
Olodaterol 5 μg 1.564 (0.017)c 0.089 (0.017) <0.0001 3.319 (0.037)a 0.107 (0.031) 0.0006
Olodaterol 10 μg 1.576 (0.017)c 0.101 (0.017) <0.0001 3.310 (0.037)a 0.098 (0.031) 0.0017
Placebo 60 (post-dose) 1.473 (0.019)a 3.187 (0.034)b
Olodaterol 5 μg 1.698 (0.019)c 0.224 (0.017) <0.0001 3.471 (0.034)a 0.285 (0.029) <0.0001
Olodaterol 10 μg 1.699 (0.019)c 0.226 (0.017) <0.0001 3.477 (0.034)a 0.290 (0.029) <0.0001
Study 1222.38
Placebo −0.30 (pre-dose/trough) 1.520 (0.024)d 3.103 (0.039)d
Olodaterol 5 μg 1.630 (0.025)e 0.110 (0.019) <0.0001 3.222 (0.040)e 0.119 (0.036) 0.0013
Olodaterol 10 μg 1.630 (0.025)f 0.110 (0.019) <0.0001 3.222 (0.040)f 0.119 (0.037) 0.0013
Placebo 60 (post-dose) 1.577 (0.026)d 3.144 (0.039)d
Olodaterol 5 μg 1.768 (0.026)e 0.192 (0.021) <0.0001 3.409 (0.040)e 0.265 (0.035) <0.0001
Olodaterol 10 μg 1.771 (0.026)f 0.195 (0.021) <0.0001 3.425 (0.040)f 0.281 (0.035) <0.0001
an = 136; bn = 135; cn = 137; dn = 146; en = 143; fn = 139
Common baseline means (SE): Study 1222.37, FEV1, 1.478 (0.043); FVC, 3.221 (0.073). Study 1222.38, FEV1, 1.553 (0.043); FVC, 3.160 (0.072)
SE standard error, FEV1 forced expiratory volume in 1 s, FVC forced vital capacity
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effect sizes of the study medication on exercise cap-
acity to some extent.
The multifactorial nature of exercise limitation in
patients with COPD may also contribute to the vari-
ability in exercise response to bronchodilators from
one study to another. This phenomenon is illustrated
by the results of replicate studies with tiotropium
[13, 15], in which similar lung-function improve-
ments resulted in notable differences in the magni-
tude of improvement in endurance time, varying
from 21 % in the first study to 40 % in the second
study.
Table 5 Adjusted mean body plethysmography outcomes at 6 weeks: IC and FRC (full analysis set)
IC FRC
Treatment Planned time (min) na Mean (SE) IC, L Mean (SE) difference
from placebo, L
p value Mean (SE) FRC, L Mean (SE) difference
from placebo, L
p value
Study 1222.37
Placebo −30 (pre-dose/trough) 134-135 2.170 (0.040) 4.977 (0.062)
Olodaterol
5 μg
139-140 2.289 (0.040) 0.119 (0.034) 0.0005 4.855 (0.061) −0.122 (0.069) 0.0784
Olodaterol
10 μg
134 2.262 (0.040) 0.092 (0.034) 0.0073 4.862 (0.062) −0.115 (0.070) 0.1013
Placebo 60 (post-dose) 134-135 2.221 (0.040) 4.950 (0.064)
Olodaterol
5 μg
139-140 2.427 (0.040) 0.206 (0.035) <0.0001 4.740 (0.063) −0.210 (0.066) 0.0015
Olodaterol
10 μg
134 2.437 (0.040) 0.216 (0.036) <0.0001 4.577 (0.064) −0.373 (0.066) <0.0001
Study 1222.38
Placebo −30 (pre-dose/trough) 147 2.463 (0.041) 4.842 (0.062)
Olodaterol
5 μg
145-146 2.613 (0.041) 0.150 (0.040) 0.0002 4.757 (0.063) −0.086 (0.053) 0.1048
Olodaterol
10 μg
141-142 2.618 (0.042) 0.154 (0.040) 0.0001 4.723 (0.063) −0.120 (0.053) 0.0246
Placebo 60 (post-dose) 147 2.493 (0.040) 4.770 (0.065)
Olodaterol
5 μg
145-146 2.725 (0.040) 0.232 (0.036) <0.0001 4.557 (0.065) −0.213 (0.053) <0.0001
Olodaterol
10 μg
141-142 2.696 (0.040) 0.203 (0.036) <0.0001 4.583 (0.065) −0.187 (0.054) 0.0005
aN numbers for IC and FRC
IC inspiratory capacity, FRC forced residual capacity, SE standard error
Table 6 Common adverse eventsa (treated setb)
Study 1222.37, n (%) Study 1222.38, n (%)
Placebo Olodaterol 5 μg Olodaterol 10 μg Placebo Olodaterol 5 μg Olodaterol 10 μg
(n = 143) (n = 147) (n = 143) (n = 149) (n = 150) (n = 147)
Any adverse event 38 (26.6) 49 (33.3) 42 (29.4) 34 (22.8) 42 (28.0) 31 (21.1)
Serious adverse event 3 (2.1) 3 (2.0) 3 (2.1) 3 (2.0) 8 (5.3) 3 (2.0)
Adverse event leading to discontinuation 4 (2.8) 4 (2.7) 2 (1.4) 1 (0.7) 2 (1.3) 0 (0.0)
Most common adverse events
COPD exacerbation
Nasopharyngitis
Insomnia
Headache
Dyspnoea
Cough
Oropharyngeal pain
10 (7.0)
4 (2.8)
0 (0.0)
1 (0.7)
3 (2.1)
2 (1.4)
1 (0.7)
11 (7.5)
3 (2.0)
2 (1.4)
4 (2.7)
4 (2.7)
1 (0.7)
0 (0.0)
7 (4.9)
1 (0.7)
3 (2.1)
2 (1.4)
2 (1.4)
3 (2.1)
3 (2.1)
10 (6.7)
3 (2.0)
0 (0.0)
0 (0.0)
0 (0.0)
2 (1.3)
0 (0.0)
9 (6.0)
2 (1.3)
0 (0.0)
2 (1.3)
1 (0.7)
1 (0.7)
0 (0.0)
4 (2.7)
7 (4.8)
0 (0.0)
2 (1.4)
2 (1.4)
0 (0.0)
0 (0.0)
aWith incidence ≥2 %; b4 patients in Study 1222.37 and 3 in Study 1222.38 were included in the treated set but not the full analysis set because they did not have
baseline or primary end point data
COPD chronic obstructive pulmonary disease
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An unexpected finding in the present studies was the
reduction in endurance time in the placebo group after
6 weeks of treatment, compared to pre-randomisation
baseline, which has not been observed in previous studies.
Whether this was a reflection of a time-dependent decrease
in exercise capacity over the 23-week observation period or
a deterioration related to the lack of optimal bronchodila-
tion in the placebo group is difficult to ascertain because
only a single, pre-randomisation baseline exercise test was
included to limit the burden on study participants.
However, the concomitant reduction in IC that was
also observed prior to exercise in the placebo group
would argue for the latter explanation. A reduction in
post-treatment exercise endurance, compared to pre-
randomisation baseline, was also observed in the placebo
groups of two recently completed, replicate, 6-week,
crossover trials of similar design (NCT01533922 and
NCT01533935; manuscript in preparation), while in a
12-week, parallel-group, exercise study, exercise endurance
time in the placebo group was reduced after 6 weeks,
but increased after 12 weeks, compared to baseline
(NCT01525615; manuscript in preparation).
Conclusions
These two studies demonstrated that olodaterol 5 μg
and 10 μg both improved exercise endurance time after
6 weeks of treatment compared to placebo, likely as a
consequence of reductions in hyperinflation prior to
exercise, which were maintained during exercise.
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